HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.